The pharmacokinetics of abacavir 600mg once daily in HIV-1-positive pregnant women (Record no. 76391)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01840cam a2200169 4500 |
| 001 - CONTROL NUMBER | |
| control field | NMDX7528 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 120401t2016 xxu||||| |||| 00| 0 eng d |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Wood, C. |
| 240 ## - UNIFORM TITLE | |
| Uniform title | <a href="AIDS">AIDS</a> |
| 245 ## - TITLE STATEMENT | |
| Title | The pharmacokinetics of abacavir 600mg once daily in HIV-1-positive pregnant women |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Date of publication, distribution, etc. | 2016 |
| 500 ## - GENERAL NOTE | |
| General note | NMUH Staff Publications |
| 500 ## - GENERAL NOTE | |
| General note | EMBASE |
| 500 ## - GENERAL NOTE | |
| General note | 30 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | <span style="font-size: 10pt;">Objective: To describe the pharmacokinetics of abacavir 600mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum. Design: A nonrandomized, open-label, multicentre, phase-IV study. Methods: HIV-positive pregnant women receiving abacavir 600mg q.d. as part of clinical care were included. Intensive 24-h pharmacokinetic sampling was performed during the third trimester and at least 2 weeks after delivery. Pharmacokinetic parameters were calculated by noncompartmental analysis. Paired cord blood and maternal blood samples were taken at delivery when feasible. Results: A total of 14 women were included in the analysis. Geometric mean ratios (90% confidence intervals) of third trimester versus postpartum were 1.05 (0.92-1.19) for AUC 0-24h and 1.00 (0.83-1.21) for C max. The median (range) ratio of abacavir cord plasma to maternal plasma was 1.0 (0.7-1.0, n=3). Viral load at the third trimester visit was less than 50copies/ml in 13 participants (93%; one unknown). In total, 13 (93%; one unknown) children were tested HIV-negative. Conclusion: The pharmacokinetics of abacavir 600mg q.d. during pregnancy are equivalent to postpartum. No dose adjustments are required during pregnancy and similar antiviral activity is expected&nbsp;</span> |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://journals.lww.com/aidsonline/Fulltext/2016/05150/The_pharmacokinetics_of_abacavir_600_mg_once_daily.9.aspx">http://journals.lww.com/aidsonline/Fulltext/2016/05150/The_pharmacokinetics_of_abacavir_600_mg_once_daily.9.aspx</a> |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection code | Home library | Current library | Shelving location | Date acquired | Total Checkouts | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Staff publications for NMDX | Ferriman information and Library Service (North Middlesex) | Ferriman information and Library Service (North Middlesex) | Shelves | 07/06/2022 | 07/06/2022 | 07/06/2022 | Book |